Akèy › Tit travay › Validation Engineer III
Validation Engineer III: Salè H-1B
46 aplikasyon kondisyon travay te itilize tit travay Validation Engineer III. Salè baz medyàn ofri $105,000; mwatye mitan $98,405–$118,889.
Avoka imigrasyon, rekritè oswa anplwayè? Mete sèvis ou an tèt paj sa a — $99 pou 30 jou →
Anplwayè yo
| Anplwayè | LCA | Salè medyan |
|---|---|---|
| FUJIFILM Diosynth Biotechnologies Texas LLC | 9 | $105,000 |
| Azzur Group DBA, Azzur Consulting LLC | 6 | $111,695 |
| Emd Millipore Corporation | 4 | $107,500 |
| Gilead Sciences, Inc. | 3 | $138,174 |
| Verista Inc (fka Delta Project Management, Inc.) | 2 | $127,348 |
| Thermo Fisher Scientific Inc. | 2 | $97,771 |
| Kashiv BioSciences LLC | 2 | $128,000 |
| AGC Biologics, Inc. | 2 | $99,822 |
| Azzur Group LLC dba Azzur Consulting LLC | 2 | $95,000 |
| Amneal Pharmaceuticals, LLC | 1 | $87,422 |
| Verista, Inc. | 1 | $120,120 |
| SAS Info Inc | 1 | $79,664 |
| Arrowtek Technologies, LLC | 1 | $115,000 |
| PSC Biotech Corporation | 1 | $83,782 |
| Lonza Houston Inc | 1 | $84,656 |
| Genezen MA, Inc. | 1 | $113,629 |
| Ocular Therapeutix, Inc. | 1 | $98,405 |
| Curia Global, Inc. | 1 | $132,351 |
| Anika Therapeutics, Inc. | 1 | $98,405 |
| Rocket Pharmaceuticals, Inc. | 1 | $147,518 |
| KBI Biopharma, Inc. | 1 | $109,741 |
| Exela Pharma Sciences, LLC | 1 | $102,000 |
| Just-Evotec Biologics, Inc. | 1 | $127,000 |
Pa nivo salè
| Nivo revni | Salè medyan |
|---|---|
| Nivo I (antre) | $95,000 |
| Nivo II (kalifye) | $100,548 |
| Nivo III (eksperyans) | $105,000 |
| Nivo IV (plen kompetans) | $138,174 |
Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.
Pa ane fiskal
| Ane fiskal | LCA | Salè medyan |
|---|---|---|
| FY2023 | 10 | $105,000 |
| FY2024 | 17 | $100,548 |
| FY2025 | 16 | $107,692 |
| FY2026 | 3 | $102,000 |
Vil yo
- College Station, TX8
- Piscataway, NJ3
- Oceanside, CA3
- Jaffrey, NH3
- Bedford, MA3
- Portsmouth, NH2
- Hatboro, PA2
- Bothell, WA2
- Morrisville, NC2
- Cambridge, MA1
- Bryan, TX1
- Sanford, NC1
- Palinville, MA1
- Spokane, WA1
- Newbury Park, CA1
- High Point, NC1
- Houston, TX1
- Waltham, MA1
- Irvine, CA1
- Lexington, MA1
- Burlington, MA1
- La Verne, CA1
- San Diego, CA1
- Cranbury, NJ1
- Raleigh, NC1
- Lenoir, NC1
- Redmond, WA1
Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).